Equities

Sirnaomics Ltd

Sirnaomics Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (HKD)3.03
  • Today's Change0.06 / 2.02%
  • Shares traded83.60k
  • 1 Year change-93.45%
  • Beta--
Data delayed at least 15 minutes, as of Nov 08 2024 07:59 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of USD
(except for per share items)
Fiscal data as of Dec 31 2023202320222021
ASSETS
Cash And Short Term Investments44105212
Total Receivables, Net------
Total Inventory------
Prepaid expenses151212
Other current assets, total--00.06
Total current assets59117224
Property, plant & equipment, net153015
Goodwill, net------
Intangibles, net0.820.921.07
Long term investments--15--
Note receivable - long term------
Other long term assets0.761.241.06
Total assets76164241
LIABILITIES
Accounts payable3.874.891.48
Accrued expenses6.936.1512
Notes payable/short-term debt000
Current portion long-term debt/capital leases1.181.751.35
Other current liabilities, total1.031.431.50
Total current liabilities131416
Total long term debt383814
Total debt394015
Deferred income tax------
Minority interest(16)(10)(1.33)
Other liabilities, total------
Total liabilities364229
SHAREHOLDERS EQUITY
Common stock0.090.090.09
Additional paid-in capital514519517
Retained earnings (accumulated deficit)(471)(393)(304)
Treasury stock - common0(1.21)0
Unrealized gain (loss)------
Other equity, total(3.23)(3.03)(1.25)
Total equity40122212
Total liabilities & shareholders' equity76164241
Total common shares outstanding888888
Treasury shares - common primary issue00.170
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.